Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial

Journal of the National Cancer Institute
Peter S GrimisonGuy C Toner

Abstract

The Australian and New Zealand Germ Cell Trials Group conducted a multicenter randomized phase III trial in men with good-prognosis germ cell tumors of two standard chemotherapy regimens that contained bleomycin, etoposide, and cisplatin but differed in the scheduling and total dose of cisplatin, the total dose of bleomycin, and the scheduling and dose intensity of etoposide. The trial was stopped early at a median follow-up of 33 months after a planned interim analysis found a survival benefit for the more dose-intense regimen. The aim of this analysis was to determine if this survival benefit was maintained with long-term follow-up. Between February 1994 and April 2000, 166 men with good-prognosis metastatic germ cell tumors defined by modified Memorial Sloan-Kettering criteria were randomly assigned to receive 3B(90)E(500)P (three cycles, repeated every 21 days, of 30 kU bleomycin on days 1, 8, and 15; 100 mg/m(2) etoposide on days 1-5; and 20 mg/m(2) cisplatin on days 1-5; n = 83) or 4B(30)E(360)P (four cycles, repeated every 21 days, of 30 kU bleomycin on day 1, 120 mg/m(2) etoposide on days 1-3, and 100 mg/m(2) cisplatin on day 1; n = 83). Endpoints included overall survival, progression-free survival, and quality of life...Continue Reading

References

Jul 25, 1992·BMJ : British Medical Journal·S J Pocock
Aug 22, 1992·BMJ : British Medical Journal·E J Neale
Oct 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G C TonerM J Morse
Jan 1, 1990·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A CoatesD McNeil
Jun 4, 1987·The New England Journal of Medicine·S D WilliamsP J Loehrer
Aug 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J BoslR Carey
Mar 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L H EinhornF A Greco
May 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D BajorinG J Bosl
Jan 1, 1981·Journal of Chronic Diseases·W O SpitzerB R Catchlove
Feb 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J LoehrerD Trump
Jul 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A LeviZ Kerestes
Apr 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D F BajorinP Sogani
Feb 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S B SaxmanL H Einhorn
Nov 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A SloanN L Vaught
Jan 6, 2004·Journal of Pharmaceutical Sciences·John H Ansede, Dhiren R Thakker
Jun 5, 2004·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·J FleerJ E H M Hoekstra-Weebers
Jun 16, 2004·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Almarie UysRonald Anderson
Aug 11, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Karim FizaziChristopher J Logothetis
Jan 26, 2005·European Journal of Clinical Investigation·J NuverJ A Gietema
May 24, 2005·Urologic Oncology·Alv A DahlSophie D Fosså
Mar 7, 2006·Lancet·Alan HorwichRobert Huddart
Nov 29, 2007·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Guro E LindRagnhild A Lothe
Apr 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Esther C de HaasJourik A Gietema
Jun 11, 2009·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Peter S GrimisonMartin R Stockler

❮ Previous
Next ❯

Citations

Nov 20, 2013·Der Urologe. Ausg. A·S Krege
Jan 1, 2013·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·I N OlverUNKNOWN Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Jul 16, 2010·Journal of the National Cancer Institute·Craig Nichols, Christian Kollmannsberger
Apr 5, 2014·Der Urologe. Ausg. A·F ZengerlingM Schrader
Dec 21, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P S GrimisonUNKNOWN Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Jan 15, 2013·Critical Reviews in Oncology/hematology·Marios FroudarakisEvangelos Briasoulis
Aug 1, 2012·Seminars in Oncology Nursing·Melissa Viatori
Jun 21, 2011·European Urology·Robert AbouassalyCora N Sternberg
May 17, 2011·Hematology/oncology Clinics of North America·Craig Nichols, Christian Kollmannsberger
May 17, 2011·Hematology/oncology Clinics of North America·Peter W M Chung, Philippe Bedard
Mar 5, 2014·CA: a Cancer Journal for Clinicians·Susanna B ParkMatthew C Kiernan
May 7, 2014·Basic & Clinical Pharmacology & Toxicology·Ahmed H Zedan, Ole J Vilholm
Dec 19, 2014·Pediatrics International : Official Journal of the Japan Pediatric Society·Jia-Shiuan LiRen-Hung Huang
Mar 23, 2012·International Journal of Radiation Oncology, Biology, Physics·Richard B WilderClair J Beard
Jan 7, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Toyomi SatohHiroyuki Yoshikawa
Nov 23, 2005·Urologic Oncology·Robert AbouassalyDerek Raghavan
Feb 24, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jakob LauritsenGedske Daugaard
Feb 28, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Furqan ShaikhA Lindsay Frazier
Feb 4, 2019·The Medical Journal of Australia·Angelina TjokrowidjajaCraig R Lewis
Jan 1, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Alpaslan OzgunOguz Bilgi
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas A OlsonA Lindsay Frazier
Aug 14, 2019·Journal of Oncology Practice·Adriana FonsecaFurqan Shaikh
Sep 21, 2018·American Society of Clinical Oncology Educational Book·Darren R Feldman
Jun 18, 2021·Patient Related Outcome Measures·Rebecca Mercieca-BebberMartin R Stockler
Oct 31, 2020·European Urology Focus·Ragheed M SaoudScott Eggener
Apr 15, 2011·Current Opinion in Oncology

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
Stéphane CulineGenito-Urinary Group of the French Federation of Cancer Center (GETUG T93BP)
Hematology/oncology Clinics of North America
Mary Gospodarowicz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Johannes ClassenMichael Bamberg
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Xavier Garcia-del-MuroJosep R Germá-Lluch
Annals of Oncology : Official Journal of the European Society for Medical Oncology
H-J SchmollESMO Guidelines Working Group
© 2021 Meta ULC. All rights reserved